TMO vs BIO

For growth investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus 0. 7% for Bio-Rad Laboratories, Inc. (BIO). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 3x trailing P/E (25. 2x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 9. 3x versus Thermo Fisher Scientific Inc. at 26. 7x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +2. 1%, compared to -57. 0% for Bio-Rad Laboratories, Inc. (BIO). Over 10 years, the gap is even starker: TMO returned +229. 1% versus BIO's +82. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 92β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately 19% more volatile than BIO relative to the S&P 500. On balance sheet safety, Bio-Rad Laboratories, Inc. (BIO) carries a lower debt/equity ratio of 21% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Thermo Fisher Scientific Inc.

(TMO) is pulling ahead at 3. 9% versus 0. 7% for Bio-Rad Laboratories, Inc. (BIO). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Over a 3-year CAGR, TMO leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus 15. 1% for Thermo Fisher Scientific Inc. — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus 10. 5% for BIO. At the gross margin level — before operating expenses — BIO leads at 52. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Thermo Fisher Scientific Inc.

(TMO) trades at 19. 0x forward P/E versus 25. 2x for Bio-Rad Laboratories, Inc. — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 4% to $654. 67.

In this comparison, TMO (0.

4% yield) pays a dividend. BIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bio-Rad Laboratories, Inc.

(BIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92)). Both have compounded well over 10 years (BIO: +82. 9%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TMO is a mid-cap quality compounder stock; BIO is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.